The pricing policy of KV was heavily criticized as it substantially increased medication cost and removed less expensive alternatives [REF].
By the end of March the FDA announced that pharmacies compounding the drug independently will not face legal reprisal, thus enabling the price of the drug to remain in the $10-20 range [REF].